DIFFUSE INTRINSIC PONTINE GLIOMA

This study tests a cancer vaccine called SurVaxM in 35 children whose brain tumors have come back or are hard to treat. The vaccine teaches the immune system to find and destroy tumor cells. The goal is to see if it is safe and helps control the disease.

This early-stage study tests a new treatment for children and young adults with certain hard-to-treat brain tumors, including DIPG and DMG. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack tumor cells, then delivered directly …

This early-stage trial tests a personalized treatment for children with recurrent neuroblastoma or a newly diagnosed brainstem tumor called DIPG. The approach combines targeted drugs with the child's own immune cells and stem cells, all customized to their tumor. The main goal is…

This study tested two experimental drugs, atengenal and astugenal, for a rare and aggressive brain tumor called DIPG that mainly affects children. The goal was to see if the treatment could shrink tumors and help people live longer. Only one person enrolled before the study was s…

This study is testing a new drug called PTC596 (Unesbulin) given alongside radiation therapy for children and teens (ages 1-21) newly diagnosed with aggressive brain tumors like DIPG or high-grade glioma. The main goal is to find a safe dose and check for side effects. Participan…

This study tests a drug called indoximod, which aims to help the immune system fight brain tumors. It is for children aged 3 to 21 with certain types of progressive brain cancer or a newly diagnosed brainstem tumor (DIPG). Participants receive indoximod alongside standard chemoth…

This study looks at whether a wearable device called Optune is safe and practical for children with aggressive brain tumors. In one group, kids with recurrent high-grade glioma or ependymoma use the device alone. In another group, children with newly diagnosed DIPG use the device…